Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rasagiline
Drug ID BADD_D02441
Description Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Marketing Status approved
ATC Code N04BD02
DrugBank ID DB01367
KEGG ID D08469; D10829
MeSH ID C031967
PubChem ID 3052776
TTD Drug ID D06OMW
NDC Product Code 16714-770; 0093-3061; 67877-260; 47781-683; 42291-780; 67877-259; 16714-771; 0093-3060; 42571-221; 47781-690; 42571-220; 42291-779
UNII 003N66TS6T
Synonyms rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect
Chemical Information
Molecular Formula C12H13N
CAS Registry Number 136236-51-6
SMILES C#CCNC1CCC2=CC=CC=C12
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Faecaloma07.01.03.0040.001624%Not Available
Colitis microscopic07.08.01.0110.004871%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.010392%
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.001624%Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.001624%Not Available
Prostate cancer21.04.02.002; 16.25.01.0010.001624%Not Available
Freezing phenomenon17.01.05.0060.003247%Not Available
Adverse event08.06.01.0100.007144%Not Available
Impulse-control disorder19.18.01.0020.019485%Not Available
Ischaemic stroke24.04.06.010; 17.08.01.0180.002436%Not Available
Mental disorder19.07.01.0020.001624%Not Available
Motor dysfunction17.01.02.031; 15.05.06.0060.003572%Not Available
Cardiac valve disease02.07.02.0010.001624%Not Available
Abnormal behaviour19.01.01.0010.004871%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.009742%
Psychiatric symptom19.01.02.0010.001624%Not Available
Parkinson's disease17.01.05.0100.017374%Not Available
Autonomic neuropathy17.05.01.0090.002436%Not Available
Disease progression08.01.03.0380.007956%
Psychotic disorder19.03.01.0020.004384%
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.001624%Not Available
Cerebral hypoperfusion24.03.05.008; 17.08.02.011; 12.02.01.0140.001624%Not Available
Hypersexuality19.08.03.0050.011528%Not Available
Psychiatric decompensation19.01.02.0100.001624%Not Available
Dementia with Lewy bodies19.20.02.003; 17.03.01.0040.001624%Not Available
Acute kidney injury20.01.03.0160.005683%
Gambling disorder19.07.06.0150.010392%Not Available
Impulsive behaviour19.18.01.0010.004059%Not Available
Jealous delusion19.10.01.0060.001624%Not Available
Throat cancer22.08.02.008; 16.19.02.0070.001624%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages